Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria
OBJECTIVE: The responses of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) were assessed after the patients were put on various combinations of danazol, prednisolone, and cyclosporine. METHODS: Nineteen males and 13 females aged between 14 and 60 years with confirmed diagnosis of PNH wer...
| Published in: | Turkish Journal of Hematology |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Turkish Society of Hematology
2013-12-01
|
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-80664 |
| _version_ | 1848651635730939904 |
|---|---|
| author | Kanjaksha Ghosh Manisha Madkaikar Maya Gupta Farah Jijina |
| author_facet | Kanjaksha Ghosh Manisha Madkaikar Maya Gupta Farah Jijina |
| author_sort | Kanjaksha Ghosh |
| collection | DOAJ |
| container_title | Turkish Journal of Hematology |
| description | OBJECTIVE: The responses of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) were assessed after the patients were put on various combinations of danazol, prednisolone, and cyclosporine. METHODS: Nineteen males and 13 females aged between 14 and 60 years with confirmed diagnosis of PNH were treated with danazol (4), danazol + cyclosporine (7), cyclosporine (1), and prednisolone + danazol (20). Response to these interventions was assessed regularly. Danazol was added to cyclosporine in patients with aplastic bone marrow after 3 months of cyclocporine use only unless the former therapy was successful. Four patients with aplastic marrow received only danazol because they had renal insufficiency at presentation. Patients were evaluated with regular complete blood count and routine liver and renal function tests. RESULTS: One patient responded to cyclosporine only. Thirteen of 32 patients (40%) had complete response, 12/32 patients (37%) had partial response leading to freedom from red cell transfusion, and 2/32 (7%) had no response. Five patients (16%) died due to thrombosis or hemorrhage within 3 months of therapy before their response to therapy could be assessed. The median period of review of the cases was 4 years and 6 months. CONCLUSION: Danazol is a useful addition to PNH therapy both in combination with cyclosporine for hypoplastic PNH and with prednisolone for other forms of PNH, and this therapy could be a good alternative where eculizumab and anti-lymphocyte globulin cannot be used for various reasons. |
| format | Article |
| id | doaj-e38cd860be5541708b2d8f6d7d0660ae |
| institution | Directory of Open Access Journals |
| issn | 1308-5263 |
| language | English |
| publishDate | 2013-12-01 |
| publisher | Turkish Society of Hematology |
| record_format | Article |
| spelling | doaj-e38cd860be5541708b2d8f6d7d0660ae2025-11-03T00:27:55ZengTurkish Society of HematologyTurkish Journal of Hematology1308-52632013-12-0130436637010.4274/Tjh.2012.0199TJH-80664Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal HemoglobinuriaKanjaksha Ghosh0Manisha Madkaikar1Maya Gupta2Farah Jijina3National Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaNational Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaNational Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaNational Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaOBJECTIVE: The responses of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) were assessed after the patients were put on various combinations of danazol, prednisolone, and cyclosporine. METHODS: Nineteen males and 13 females aged between 14 and 60 years with confirmed diagnosis of PNH were treated with danazol (4), danazol + cyclosporine (7), cyclosporine (1), and prednisolone + danazol (20). Response to these interventions was assessed regularly. Danazol was added to cyclosporine in patients with aplastic bone marrow after 3 months of cyclocporine use only unless the former therapy was successful. Four patients with aplastic marrow received only danazol because they had renal insufficiency at presentation. Patients were evaluated with regular complete blood count and routine liver and renal function tests. RESULTS: One patient responded to cyclosporine only. Thirteen of 32 patients (40%) had complete response, 12/32 patients (37%) had partial response leading to freedom from red cell transfusion, and 2/32 (7%) had no response. Five patients (16%) died due to thrombosis or hemorrhage within 3 months of therapy before their response to therapy could be assessed. The median period of review of the cases was 4 years and 6 months. CONCLUSION: Danazol is a useful addition to PNH therapy both in combination with cyclosporine for hypoplastic PNH and with prednisolone for other forms of PNH, and this therapy could be a good alternative where eculizumab and anti-lymphocyte globulin cannot be used for various reasons.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-80664cyclosporinedanazolhemoglobinuriaparoxysmalimmunosuppressionprednisolone |
| spellingShingle | Kanjaksha Ghosh Manisha Madkaikar Maya Gupta Farah Jijina Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria cyclosporine danazol hemoglobinuria paroxysmal immunosuppression prednisolone |
| title | Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria |
| title_full | Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria |
| title_fullStr | Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria |
| title_full_unstemmed | Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria |
| title_short | Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria |
| title_sort | evaluation of danazol cyclosporine and prednisolone as single agent or in combination for paroxysmal nocturnal hemoglobinuria |
| topic | cyclosporine danazol hemoglobinuria paroxysmal immunosuppression prednisolone |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-80664 |
| work_keys_str_mv | AT kanjakshaghosh evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria AT manishamadkaikar evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria AT mayagupta evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria AT farahjijina evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria |
